# Financial Results
# First-Half (Interim period) of Fiscal 2025

November 10, 2025

KYORIN Pharmaceutical Co., Ltd.
Representative Director, President and CEO
**Yutaka Ogihara**

- **Outline of Consolidated Financial Results for Interim Period**
- **Consolidated Financial Forecast**
- **Medium-Term Business Plan of “Vision 110 –Stage 1–”**
  - **Initiative for FY2025 First Half**
  - **Status of R&D Pipeline**
  - **Trends of Mainstay Products**
- **Shareholder Returns**
- **Reduction of Cross-Shareholdings**

# Outline of Consolidated Financial Results for Interim Period

# Outline of Consolidated Financial Results for Interim Period

（Units: JPY billions）

| | | FY2024 1H | FY2025 1H | Year on year | |
|---|---|---|---|---|---|
| | | | | Change | Change (%) |
| Net sales | | 55.1 | **58.7** | +3.6 | +6.5 |
| | New drugs, etc. (Japan) | 39.0 | **41.4** | +2.4 | +6.1 |
| | New drugs (overseas) | 0.4 | **0.5** | +0.1 | +18.8 |
| | Generic drugs | 15.7 | **16.8** | +1.1 | +7.2 |
| Cost of sales | | 31.6 | **33.8** | +2.2 | +7.2 |
| Gross profit | | 23.6 | **24.9** | +1.3 | +5.7 |
| SG&A | | 22.0 | **23.5** | +1.5 | +6.9 |
| (R&D) | | (3.8) | **(5.4)** | (+1.6) | (+41.6) |
| Operating profit | | 1.5 | **1.4** | -0.1 | -12.0 |
| Ordinary profit | | 2.1 | **1.6** | -0.5 | -22.8 |
| Profit attributable to owners of parent | | 1.3 | **1.5** | +0.2 | +19.0 |

# Highlights of Business Performance (1/3) YoY: Net Sales

(Units: JPY billions)




( year on year)

| | | |
|---|---|---|
| New drugs, etc. (Japan） | 41.4 | +2.4 |

Factor of increase

- New drugs grew (Beova, Lasvic and Lyfnua, etc.)

Factor of decrease

- NHI drug price revisions (Kyorin Pharmaceutical: 5% range)

| | | |
|---|---|---|
| New drugs (Overseas) | 0.5 | +0.1 |

| | | |
|---|---|---|
| Generic drugs | 16.8 | +1.1 |

- Increase sales in new listed products in FY2024
- Impact of the new health coverage rule for long-listed products

# Highlights of Business Performance (2/3) YoY: Operating Profit




( year on year)

| | | |
|---|---|---|
| **Gross profit** | **24.9** | **+1.3** |

Net sales **+3.6**

Cost of sales ratio **+0.3%pt**

Factor of Increase
- NHI drug price revisions (Kyorin Pharmaceutical: 5% range)
- Increase sales in generic drugs

Factor of Decrease
Increase in sales of new drugs (Beova, Lasvic, Lyfnua, etc.)

| | | |
|---|---|---|
| **R&D expenses** | **5.4** | **+1.6** |

3.8 (FY2024 1H) ⇒ 5.4 (FY2025 1H)

- Upfront payment for in-license product (KRP-A225) 1.5 billion yen

| | | |
|---|---|---|
| **SG&A (excluding R&D)** | **18.1** | **-0.1** |

18.2 (FY2024 1H) ⇒ 18.1 (FY2025 1H)

- Cost reduction through head office relocation etc.
- Increase in license fees, etc.

# Highlights of Business Performance (3/3) : Vs Forecast

（Units: JPY billions）

| | | FY2025 1H (forecast) | FY2025 1H | Vs. forecast | |
|---|---|---|---|---|---|
| | | | | Change | Achievement rate (%) |
| Net sales | | 57.4 | **58.7** | +1.3 | 102.3 |
| | New drugs, etc. (Japan) | 40.7 | **41.4** | +0.7 | 101.7 |
| | New drugs (overseas) | 0.1 | **0.5** | +0.4 | 504.1 |
| | Generic drugs | 16.5 | **16.8** | +0.3 | 102.0 |
| Cost of sales | | — | **33.8** | — | — |
| Gross profit | | — | **24.9** | — | — |
| SG&A | | — | **23.5** | — | — |
| (R&D) | | (4.3) | **(5.4)** | (+1.1) | (126.6) |
| Operating profit | | 1.7 | **1.4** | -0.3 | 80.2 |
| Ordinary profit | | 1.8 | **1.6** | -0.2 | 87.9 |
| Profit attributable to owners of parent | | 1.4 | **1.5** | +0.1 | 106.7 |

**Difference from the Forecast announced on May 12, 2025**

Net sales: Interim forecasts were exceeded due to the growth of new drugs such as Beova and income related to Gatifloxacin.

Operating profit: R&D expenses included a upfront payment of 1.5 billion yen associated with KRP-A225, resulting in a shortfall of 0.3 billion yen.

Profit attributable to owners of parent: Extraordinary income included a 0.4 billion yen gain on the sale of investment securities, etc.

# Mainstay Product Sales Update

(Units: JPY billions)

| | | FY2024 1H | FY2025 1H | Year on year | | FY2025 1H (Forecast) announced on May 12, 2025 | Vs. forecast | |
|---|---|---|---|---|---|---|---|---|
| | | | | Change | Change (%) | | Change | Achievement rate (%) |
| New Drugs, etc. (Japan) | Beova (KYORIN) | 10.4 | 12.3 | +1.9 | +17.5 | 11.6 | +0.7 | 105.8 |
| | Lasvic | 3.0 | 3.5 | +0.5 | +19.0 | 3.7 | -0.2 | 95.2 |
| | Lyfnua | 0.4 | 0.5 | +0.1 | +9.9 | 0.5 | 0 | 93.2 |
| | Desalex | 3.4 | 3.7 | +0.3 | +8.1 | 3.6 | +0.1 | 101.8 |
| | Flutiform | 6.4 | 6.3 | -0.1 | -1.1 | 6.2 | +0.1 | 101.8 |
| | Pentasa | 6.2 | 6.3 | +0.1 | +1.4 | 5.9 | +0.4 | 106.2 |
| | Kipres | 1.8 | 0.9 | -0.9 | -48.9 | 0.8 | +0.1 | 117.2 |
| | Mucodyne | 1.5 | 2.0 | +0.5 | +30.2 | 2.2 | -0.2 | 90.1 |
| | Milton | 0.9 | 0.9 | 0 | +0.5 | 0.9 | 0 | 103.8 |
| | Rubysta | 0.6 | 0.4 | -0.2 | -31.6 | 0.5 | -0.1 | 81.6 |
| Generic Drugs | Montelukast tablets“KM” | 5.0 | 4.4 | -0.6 | -12.8 | 4.9 | -0.5 | 89.7 |
| | Mometasone Nasal 50mg “KYORIN” | 0.7 | 1.1 | +0.4 | +58.6 | 0.8 | +0.3 | 140.0 |

# Consolidated Financial Forecast

# Consolidated Financial Forecast for FY2025 *remain unchanged

(Units: JPY billions)

| | | FY2024 (Actual) | FY2025 (Forecast) | Year-on-year | |
|---|---|---|---|---|---|
| | | | | Change | Change (%) |
| Net sales | | 130.1 | **127.0** | -3.1 | -2.4 |
| | New drugs, etc. (Japan) | 84.2 | **89.0** | +4.8 | +5.8 |
| | New drugs (overseas) | 8.9 | **0.2** | -8.7 | -97.7 |
| | Generic drugs | 37.1 | **37.7** | +0.6 | +1.7 |
| Cost of sales | | 70.6 | **—** | — | — |
| SG&A | | 47.0 | **—** | — | — |
| (R&D) | | (10.5) | **(10.4)** | (-0.1) | (-1.1) |
| Operating profit | | 12.6 | **6.1** | -6.5 | -51.5 |
| Ordinary profit | | 13.2 | **6.3** | -6.9 | -52.3 |
| Profit attributable to owners of parent | | 9.1 | **4.8** | -4.3 | -47.2 |

# Forecast of Mainstay Products Sales *remain unchanged

(Units: JPY billions)

| | | FY2024 Actual | FY2025 Forecast | Year-on-year | |
|---|---|---|---|---|---|
| | | | | Change | Change (%) |
| New Drugs, etc. (Japan) | Beova (KYORIN) | 22.1 | 25.1 | +3.0 | +13.7 |
| | Lasvic | 7.8 | 8.5 | +0.7 | +8.3 |
| | Lyfnua | 0.9 | 1.1 | +0.2 | +20.4 |
| | Desalex | 9.6 | 10.1 | +0.5 | +5.0 |
| | Flutiform | 13.7 | 13.2 | -0.5 | -3.9 |
| | Pentasa | 12.2 | 11.6 | -0.6 | -4.7 |
| | Kipres | 3.5 | 2.1 | -1.4 | -40.0 |
| | Mucodyne | 3.6 | 5.2 | +1.6 | +45.8 |
| | Milton | 1.8 | 1.8 | 0 | -2.3 |
| | Rubysta | 1.1 | 1.0 | -0.1 | -9.7 |
| Generic Drugs | Montelukast tablets “KM” | 12.0 | 11.3 | -0.7 | -5.6 |
| | Mometasone Nasal 50mg “KYORIN” | 4.1 | 4.3 | +0.2 | +4.5 |

# Medium-Term Business Plan of “Vision 110 –Stage 1–”
# Initiatives for FY2025 First Half

# Vision 110
## Stage 1

- Strengthening drug discovery capability to create high-value new drugs that meet medical needs
- Expansion of development pipeline through in-licensing
- Maximization of the ratio of new drugs
- Promoting healthcare-related businesses that have synergies with the new drugs business
- Building a sustainable corporate foundation

# Strengthening drug discovery capability to create high-value new drugs that meet medical needs

## Drug discovery

Strengthening drug discovery by drug innovation

**Development of new research themes**

×

**Strengthen basic technology**

Research area

| Pain | Autoimmune disorders | Neuromuscular disease |
|---|---|---|

Newly establishing Neuromuscular Disorders as a drug discovery research area

## Neuromuscular disease

A general term for diseases that cause motor impairment (movement disorders) due to a lesion/pathology in the nerves themselves (such as the brain, spinal cord, and peripheral nerves) or in the muscles themselves.

- Amyotrophic Lateral Sclerosis (ALS)
- Parkinson's Disease (PD)
- Myasthenia Gravis (MG)
- Multiple Sclerosis (MS)
- Muscular Dystrophy
- Hereditary Neuropathies, etc.

**Etiology / Causes** Genetic mutations, autoimmunity, aging, environmental factors, etc.

# Expansion of development pipeline through in-licensing

# Expansion of development pipeline through in-licensing

**Stage1 Target**

At least six in-licensing items

**FY2025 Initiatives**

Obtain at least two in-licensed assets (including marketed products) demonstrating high potential for rapid revenue generation

**FY2025 Actual for first half**

KRP-A225 (HB2198, new drug candidate for SLE, etc.):
September 2025, Hinge Bio Inc.

# Target disease: Systemic Lupus Erythematosus - SLE

| | |
|---|---|
| Overview | ●An autoimmune disease where immune abnormalities lead to the production of autoantibodies, damaging organs<br>●Excessively produced autoantibodies form immune complexes, which deposit in tissues, leading to inflammation<br>●A designated intractable disease in Japan |
| Symptoms | ●Most patients exhibit systemic, skin, and joint symptoms<br>●Other symptoms are diverse, including visceral symptoms such as lupus nephritis, and vascular symptoms.<br>The specific symptoms and combinations vary from person to person |
| Number of patients | Estimated prevalence: Approximately 60,000 to 100,000 people<br>Number of medical certificate holders (for designated intractable disease): 66,307 (FY 2023)<br>Prevalence rate: 20 to 150 per 100,000 people* |
| Current treatments | ●Steroids ●Immunosuppressants<br>●Immunomodulatory drugs ●Biologics |

* Guideline for the management of systemic lupus erythematosus 2019

A significant unmet need for new therapeutic options remains

## Overview of KRP-A225

| | |
|---|---|
| Target disease | Systemic Lupus Erythematosus (SLE), etc. |
| MoA | B cell depletion by a humanized bispecific antibody targeting CD19 and CD20 |
| Patients | Moderate to severe patients |
| Formulation | Iv infusion |
| Development status | Phase 1 trial in preparation (targeted to start in 2025) |
| Future direction | The next steps will be determined based on the results of the Phase 1 trial conducted by Hinge Bio |



Development will be advanced in collaboration with Hinge Bio, aiming for the earliest possible market launch

# KRP-A225




A humanized bispecific antibody that features a dimeric structure of a full-length IgG antibody, generated using Hinge Bio's proprietary GEM-DIMER™ technology.

It targets the CD19 and CD20 molecules, which have clinically validated efficacy against SLE, and is expected to achieve rapid and potent B-cell depletion in the circulating blood and lymphoid tissues.

"Superdimerization" is mediated by an ACE2 receptor-derived collectrin-like domain.

The high-affinity modified Fc region is expected to enhance immune effector functions such as ADCC (Antibody-Dependent Cellular Cytotoxicity), ADCP (Antibody-Dependent Cellular Phagocytosis), and CDC (Complement-Dependent Cytotoxicity)

The antibody can be manufactured using standard antibody drug manufacturing processes.

# Status of R&D Pipeline

- No statistically significant difference was achieved in the primary endpoint
- Clinical benefit was observed across multiple study efficacy parameters

## EFZO-FIT Study

| | |
|---|---|
| Titles | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis |
| Study Design | ○ Randomized, Double-Blind, Placebo-Controlled Parallel Assignment Study<br>○ Efzofitimod 3mg/kg or 5mg/kg of Efzofitimod or placebo dosed intravenously once a month |
| Primary Outcome Measures | ● Change from baseline in mean daily oral corticosteroid (OCS) dose at week 48<br>Efzofitimod 5mg/kg: -7.9% Placebo: -7.1% \| p = 0.3313 |
| Others*<br>*Nominal p-value* | ● Steroid free at week 48<br>Efzofitimod 5mg/kg: 52.6% Placebo: 40.2% \| p = 0.0919<br>● Change from baseline in KSQ-lung<br>Efzofitimod 5mg/kg: 10.36 Placebo: 6.19 \| p = 0.0479<br>● Steroid free and KSQ-lung improvement<br>Efzofitimod 5mg/kg: 29.5% Placebo: 14.4 \| p = 0.0199 |
| Safety | Safe and well-tolerated |

*The statistical analysis plan was designed on a hierarchical assessment basis.
Therefore, since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.

**The path forward will be determined following a discussion with aTyr**

# KRP-DT123

## Results was reported by the Principal Investigator* at the 70th Congress of Japan Audiological Society

*Professor Koichiro Wasano (Department of Otorhinolaryngology, Head and Neck Surgery, Tokai University School of Medicine)

jRCTs032230359 | Primary endpoint showed a statistically significant improvement

| | |
|---|---|
| Titles | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study using the App for Tinnitus Treatment in Patients with Tinnitus (Pilot Study) |
| Target sample | 60: Chronic tinnitus patients with associated suffering |
| Primary Outcome Measures | ●Change in THI* total score from week 0 at week 16 after study app prescription *Tinnitus Handicap Inventory<br>DTx group: -16.8 Sham group: 3.6 \| p < 0.001 |




*An article under submission*

| | |
|---|---|
| Other outcome Measures | ● TFI score<br>DTx group: -16.3 Sham group: 0.3 \| p < 0.001<br>● NRS<br>Tinnitus annoyance \| p < 0.001<br>Tinnitus control \| p < 0.001<br>● HADS, AIS<br>HADS Anxiety score \| p = 0.017<br>HADS Depression score \| p = 0.082<br>Athens insomnia scale \| p = 0.027 |
| Safety | No safety issues were confirmed in the treatment group |

Sham: DTx/app that corresponds to a placebo in pharmaceutical development

**Aim to initiate the pivotal trial in the first half of FY2026**

# Status of R&D Pipeline

*Updated (As of November, 7 2025)




MRCT: Multi-Regional Clinical Trials

DTx




| | Compound/Code | Licensee | Stage | Features |
|---|---|---|---|---|
| Licensed Compound | KRP-M223* | Novartis | Pre-clinical | ●MRGPRX2 antagonist<br>●Target: allergic and inflammatory diseases involving mast cells |
| | KRP-203 | Priothera | Ph3 | ●Sphingosine-1-Phosphate receptor Agonist<br>●Target: AML patients undergoing HSCT<br>●Assignment of IP and drug substances (Sep 2020) |

# Status of R&D Pipeline/Option Agreement

| Compound/Code | Origin | Stage | Target disease | Features |
|---|---|---|---|---|
| BDT272 | BIODOL Therapeutics | Ph1 (In France) | Pain | ● Press release on Jan 2025<br>● FLT3 inhibitor<br>● Patient market of 23 million (Japan) |

**Based on the results of the Phase 1 trial, the decision on whether to transition to a licensing agreement will be made within FY2025.**

| Compound/Code | Origin | Stage | Target disease | Features |
|---|---|---|---|---|
| CYR-064 | Cyrano Therapeutics | Ph2 (In USA) | Post-viral loss of smell | ●Press release on Feb 2025<br>●PDE inhibitor<br>●Patient market of 1 million (Kyorin estimated) |

**Based on the results of the Phase 2 trial, the decision on whether to transition to a licensing agreement will be made within FY2025.**

# Maximization of the ratio of new drugs

# Maximization of the ratio of new drugs

## Ratio of new drugs | Exceeding the FY2025 target




## Product sales

The first half of FY2025 target has been achieved, and progress is on track.

Target **25.6** Actual **26.3** Progress **102.5%**



# Trends of Mainstay Products

# [Mainstay products] Beova (Therapeutic agent for OAB)




Copyright © 2025 IQVIA. Calculated based on JPM 2021-2025 (Apr-Sep), reprinted with permission




| | |
|---|---|
| Market | ● OAB market: +1.2%*1<br>● Market expansion of β3 adrenergic receptor |
| Medium to long-term market outlook | ● Number of OAB patients tend to increase<br>● Despite the impact of the NHI drug price revision, the Market for β3 adrenergic receptor is expanding |

*1 Copyright © 2025 IQVIA. Calculated based on JPM Apr-Sep 2024, Apr-Sep 2025, reprinted with permission

| | |
|---|---|
| Status in FY2025 1H | ● No.1 in OAB market sale*2<br>● No.1 share of OAB patients and rate of new patients acquisition*2<br>[NHI drug price revision: -4.32% (Apr 2025)] |
| Initiative FY2025 | ● Expand patient share in general internal medicine<br>● Enhance the consultation rate and generate consultation opportunities in urology<br>● DTC: initiative to encourage medical consultation |

*2 Combined total with partner company
Copyright©2025 IQVIA. Calculated based on JPM Apr-Sep 2025, reprinted with permission
Calculated based on IQVIA Rx.Sep 2025, reprinted with permission

# [Mainstay products] Lasvic (New quinolone synthetic antibacterial agent)









**Market**

- Oral antimicrobial market: +6.9%[*1]
- Negative rebound from last year's Mycoplasma pneumoniae epidemic

**Medium to long-term market outlook**

- Expect to tend to decrease in oral antimicrobial market due to prevent infection/appropriate use against AMR

＊1 Copyright © 2025 IQVIA. Calculated based on JPM Apr-Sep 2024, Apr-Sep 2025, reprinted with permission

**Status in FY2025 1H**

- Achieved No.1 of sales share in oral NQ market[*1]
  [NHI drug price revision: -6.21% (tab), 0.00% (iv) (Apr 2025)]

**Initiative FY2025**

- Promote treatment and therapeutic drug selection in accordance with each guideline
- Clearly define the distinctiveness and novel positioning of Lasvic

HP: Expand new adoptions at university hospitals and key regional hospitals.
GP: Promote prescription recommendations to diseases targeted for AMR action (※rhinosinusitis, tonsillitis, pharyngolaryngitis, acute bronchitis) and pneumonia.

Selective P2X3 receptor antagonist

# [Mainstay products] Lyfnua (Cough treatment)

## The number of estimated patients




## JRS Guidelines for the Management for Cough and Sputum


Revision Point

- Clearly state the recommendation levels for cough and sputum treatment
- The importance of Cough Hypersensitivity (CHS)
- Detailed explanation of refractory chronic cough

Partial modification of the JRS Guidelines for the Management for cough and Sputum 2025. p.xv Medical Review

P2X3 receptor antagonists for the management of persistent and chronic cough in adults, described on flowchart

## Sales 2H / 1H




**Status in FY2025 1H**

- The guideline was published in April 2025
- Due to the early onset of efficacy and taste-related adverse events, the persistence is short.

[NHI drug price revision: 0.0 % (Apr 2025)]

**Initiative FY2025**

- Utilized Practical guideline and new evidences
- Enhancement of better understanding for product characteristic (suppressing cough caused by nerve hypersensitivity)
- Initiative to extend the patient's period of taking drug (Promotion of proper medication counseling)

# [Mainstay products] Desalex (Antiallergic Agent)









**Market**

- Antihistamine market: -8.7%*

**Medium to long-term market outlook**

- Although the number of patients continues to increase, the market is shrinking due to the NHI drug price revision and generic drugs.

*1 Copyright © 2025 IQVIA. Calculated based on JPM 2024 Apr-Sep, Apr-Sep 2025, reprinted with permission

**Status in FY2025 1H**

- Sales increased steadily
- No.1 prescribing share in Otolaryngology*2
  [NHI drug price revision: -9.16% (Apr 2025)]

**Initiative FY2025**

- Promote prescribing to Otolaryngology and Internal Medicine
- Aim to establish a position as a drug that combines both efficacy and ease of use

*2 Copyright © 2025 IQVIA. Calculated based on IQVIA Rx Sep 2025, reprinted with permission

# [Mainstay products] Flutiform (Anti-asthmatic)









**Market**

- ICS/LABA market: -1.1%*1
- Increase to seek treatment after Covid-19, and promote to switch to generic drugs

**Medium to long-term market outlook**

- While the number of patients continues to increase, the market is forecast to remain flat due to the NHI drug price revision and generic drugs

*1 Copyright © 2025 IQVIA. Calculated based on JPM 2024 Apr-Sep, Apr-Sep 2025, reprinted with permission

**Status in FY2025 1H**

- Sales increased steadily, 3% year-on-year increase in volume.
- Market share in terms of volume:
  18.6% (Sep 2024) to 19.3% (Sep 2025) *2
  [NHI drug price revision: -5.59% (Apr 2025)]

**Initiative FY2025**

- Appeal to the utility of the aerosol formulation as suitable for patients with weak inspiratory force
- Expand prescriptions through synergy with Lyfnua promotion activities

*2 Copyright © 2025 IQVIA. Calculated based on JPM Sep 2024-Sep 2025, reprinted with permission

# Promoting healthcare-related businesses that have synergies with the new drugs business

# Status of Generic Drugs

Sales 2H/1H




Status in FY2025 1H

- Quantity growth driven by the impact of the new health coverage rule for long-listed products
- Expansion of sales for products added to the new listed products in FY2024 and key focus items
- Sales decline in AG due to the drug price revision, etc.

Sales (AG) 2H/1H




Status (AG) in FY2025 1H

- Sales decline due to the drug price revision, etc.
- Keep market share of 50% in AG

# Shareholder Returns

# Shareholders Returns

| Capital Policy | Maintain a stable dividends, taking DOE (Dividend on Equity ratio) into account |
|---|---|

Dividend

| | FY2023<br>Interim period | FY2024<br>Interim period | FY2025<br>Interim period |
|---|---|---|---|
| Interim dividend per share (Yen) | **20 yen**<br>(Annual dividend of 52 yen) | **20 yen**<br>(Annual dividend of 57 yen, which includes special dividend of 5 yen) | **20 yen**<br>(Annual dividend of 57 yen) |

○The interim dividend of 20 yen have been decided at in the Board Meeting scheduled in November 7, 2025

○The year-end dividend of 57 yen announce on May 12, 2025 remain unchanged

# Reduction of Cross-shareholdings

# Reduction of Cross-shareholdings

**Reduction Target** The ratio of Cross-shareholding to net assets to be less than 10% by 2030

- One stock was reduced in the first half of FY2025
- Aim to reduce the ratio of cross-shareholding to net assets to less than 10% ahead of schedule

| | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | change |
|---|---|---|---|---|---|---|
| Total of holdings | 25 | 21 | 20 | 20 | 19 | -1 |
| Listed | 14 | 12 | 11 | 11 | 10 | -1 |
| Unlisted | 11 | 9 | 9 | 9 | 9 | 0 |

Ref. The ratio of cross-shareholding to net assets as of the end of September 2025: 11.9%

## ●Disclaimer

This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group. These statements are based on the judgment of the Group's assumptions and outlooks based on the information and forecasts available at the time of preparation of this material, and contain known or unknown risks and uncertainties. Therefore, due to various factors that may occur, the actual performance, progress / success / failure of the development and other insights may differ significantly from the description. It also contains information about medicines (including those under development), but the description is not for the purpose of advertising or medical advice.


Kyorin